New drug cocktail aims to tackle tough lymphoma
NCT ID NCT06919939
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study is testing whether combining two drugs—epcoritamab and loncastuximab tesirine—can safely shrink or eliminate lymphoma in people whose large B-cell lymphoma has come back or not responded to treatment. About 26 adults will receive the drugs over several cycles. The main goals are to check for side effects like cytokine release syndrome and liver problems, and to see how well the cancer responds.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Epcoritamab and Loncastuximab Tesirine
What this could lead to
If this combination works, it could offer a new treatment option for people with hard-to-treat large B-cell lymphoma that has come back or not responded to prior therapy.
What could go wrong
This is a small, early-phase trial (26 people) focused on safety and side effects, not yet proven to work. The drugs can cause serious side effects like cytokine release syndrome, nerve problems, and liver issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Miami
RECRUITINGMiami, Florida, 33136, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact